Breaking News

Regis Completes Successful Audit

By Kristin Brooks | January 21, 2014

Gains approval of Control Testing Lab

Regis Technologies, Inc. has successfully passed an FDA audit with no Form 483 observations. Regis’ GMP manufacturing facility, QC lab, and quality systems were part of a detailed inspection that found the company to be in compliance with the agency’s cGMP standards.
Regis provides synthesis, separations and manufacturing services to pharma and biopharma companies for intermediates and APIs from process development and scale-up, through validation and commercial manufacturing, from its cGMP facilities outside Chicago. Regis also offers regulatory support services, as well as access to its chromatography products and services.
“The Regis team of 65 chemists and professionals has had the goal of providing the highest quality services to our customers for almost 60 years,” noted Louis Glunz, chief executive officer of Regis Technologies. “Passing this most recent week-long inspection with flying colors highlights our ongoing ability to deliver exceptional quality and regulatory reliability. This review was conducted by a highly experienced FDA reviewer and is our second consecutive FDA audit with no Form 483’s.”
Mr. Glunz added, “The FDA has also recognized and approved Regis’ profile as a Control Testing Lab, which means that our testing results can be used in our customers’ FDA submissions without the requirement that Regis be inspected as a condition for acceptance. This gives our customers greater assurance that our work will not cause them any regulatory complications or delays.”

Related Contract Manufacturing:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks